Therapeutic Response

BRAF p.V600K status confers therapeutic sensitivity to Vemurafenib in patients with Non-Langerhans Cell Histiocytosis/Erdheim-Chester Disease.

Statements

Source and description
Zelboraf (vemurafenib) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to vemurafenib for the treatment of patients with Erdheim-Chester Disease and a BRAF V600 mutation.